These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28894890)

  • 21. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
    Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
    [No Abstract]   [Full Text] [Related]  

  • 23. TERT promoter mutations in soft tissue sarcomas.
    Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
    Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
    Ko E; Seo HW; Jung ES; Kim BH; Jung G
    Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recursive partitioning analysis for survival stratification and early imaging prediction of molecular biomarker in glioma patients.
    Xie X; Luo C; Wu S; Qiao W; Deng W; Jin L; Lu J; Bu L; Duffau H; Zhang J; Yao Y
    BMC Cancer; 2024 Jul; 24(1):818. PubMed ID: 38982347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.
    Cárcano FM; Vidal DO; van Helvoort Lengert A; Neto CS; Queiroz L; Marques H; Baltazar F; da Silva Martinelli CM; Soares P; da Silva EC; Lopes LF; Reis RM
    Tumour Biol; 2016 Apr; 37(4):4901-7. PubMed ID: 26526580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.
    Harada K; Kurisu K; Tahara H; Tahara E; Ide T; Tahara E
    J Neurosurg; 2000 Oct; 93(4):618-25. PubMed ID: 11014540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
    Lee H; Lee B; Kim DG; Cho YA; Kim JS; Suh YL
    Cancer Res Treat; 2022 Jan; 54(1):75-83. PubMed ID: 33940787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
    Mosrati MA; Willander K; Falk IJ; Hermanson M; Höglund M; Stockelberg D; Wei Y; Lotfi K; Söderkvist P
    Oncotarget; 2015 Sep; 6(28):25109-20. PubMed ID: 26298771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
    Bollam SR; Berens ME; Dhruv HD
    Curr Neurol Neurosci Rep; 2018 Mar; 18(4):15. PubMed ID: 29525892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.